Recently, LNC PHARMA received the IND approval from the US FDA regarding the 177Lu-LNC1003 injection for the Phase I clinical trial, which will benefit patients with advanced prostate cancer in the near future.

177Lu-LNC1003 Injection is a PSMA-targeted radionuclide therapeutic drug. Suitable for patients with PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC). The targeting specificity of PSMA enables the delivery of radionuclide Lu-177 to the lesion site. Lu-177 is a therapeutic nuclide with an average range of 670 μm in tissues due to its relatively low β-particle energy. It has a relatively less suppressive effect on the bone marrow, which can kill tumor cells in a safer and more effective way to reduce side effects on human body.

The Relevant report on 177Lu-LNC1003 injection showed below, which was published in the European Journal of Nuclear Medicine and Molecular Imaging and sourced from the National Library of Medicine.